Pregnant Patients With Lymphoma Can Be Safely and Effectively Treated
Though lymphoproliferative diseases during pregnancy can lead to complications, a host of treatment options exists.
Lymphoma
LYMPHOMA
FEATURE
LATEST NEWS
HIV-Induced Expression of PD-L1 on Regulatory B Cells May Promote AIDS-Related NHL
HIV-induced regulatory B cells may inhibit T cell function through multiple mechanisms, potentially driving lymphomagenesis.
Increased Risk for Second Malignancy After Multiple Lines of Treatment in Follicular Lymphoma
Risk for malignancy was increased in patients who underwent 2 or 3 lines of treatment compared with patients who only underwent 1 line of treatment.
Efficacy of 19-28z CAR-T in DLBCL Unclear: Phase 1 Study Readout
The investigational treatment was associated with a high rate of neurotoxicity.
Newly Identified Mutation May Result in Venetoclax Resistance in Follicular Lymphoma
Further investigations should look at the role of acquired BCL2 mutations in venetoclax resistance.
Factors Associated With Long-Term Fatigue in Non-Hodgkin Lymphoma Survivors
Severe fatigue was more common in NHL survivors compared with the general population.
Late Relapse Rates After Immunochemotherapy Treatment for Diffuse Large B-Cell Lymphoma
Patients who achieved event-free survival at 24 months following diagnosis were evaluated for late relapses.
Using a Risk-Based System to Predict Progression From Asymptomatic Waldenström Macroglobulinemia
The model stratified patients into 3 risk groups based on median time to disease progression.
Prospective Evidence Links Textured Breast Implants to Rare Lymphoma
The risk of breast implant-associated anaplastic large cell lymphoma may be higher than previously reported for women who receive textured implants, according to researchers.
Current and Prospective Therapies for Double-Hit Lymphoma
In a review, researchers discussed the value of combining immunotherapy, targeted therapy, and chemotherapy to improve treatment for double hit lymphoma.
Response Patterns After Multiple Lines of Therapy in Mantle Cell Lymphoma
Early failure after treatment, old age, and treatment regimens not including stem cell transplantation were associated with poorer survival.
The Evolution of Frontline Hodgkin Lymphoma Treatment
With numerous options, there is growing debate over the frontline treatment of Hodgkin lymphoma.
Ibrutinib Added to R-CHOP May Improve Outcomes for Patients Younger Than 60 Years
Though the primary survival endpoints were not met in this study, younger patients experienced improved outcomes with ibrutinib.
Combined Modality Therapy May Improve Overall Survival in Pediatric Hodgkin Lymphoma
Treatment for early-stage pediatric HL can include chemotherapy with or without radiotherapy, although use of radiotherapy is waning.
Autologous Stem Cell Transplantation Outcomes in Patients With Peripheral T-Cell Lymphomas
Patients with higher International Prognostic Index scores or advanced-stage disease experienced improved survival when treated with ASCT.
Improved Progression-Free Survival in Relapsed/Refractory Indolent Lymphoma With Lenalidomide Plus Rituximab
Patients with follicular or marginal zone lymphoma who received lenalidomide with rituximab experienced a median progression-free survival of 39.4 months.
Presence of Autoimmune Diseases May Increase Risk for Diffuse Large B Cell, Marginal Zone Lymphomas
The presence of rheumatologic conditions was also associated with variations in cancer site for both diffuse large B-cell lymphoma and marginal zone lymphoma.
Challenges Remain, New Therapies Needed for Pediatric Lymphoblastic Lymphoma
Treatment for lymphoblastic lymphomas may result in high morbidity and poor prognosis, highlighting the need for novel targeted therapeutic approaches.
Consensus Panel on Maintenance Therapies Following Autologous Hematopoietic Cell Transplantation in Lymphoma
An expert panel reviewed current literature surrounding lymphoma treatment to identify and address any gaps in knowledge.
Marginal Zone Lymphoma Presentation at Multiple Mucosal Sites May Be Linked to Poorer Outcomes
Presence of multiple mucosal sites at presentation in extranodal marginal zone lymphomas may predict poor survival outcomes.
Pentostatin, Cyclophosphamide, Rituximab for Indolent Non-Hodgkin Lymphomas
The combination of pentostatin, cyclophosphamide, and rituximab yielded comparable rates of survival and adverse events to other combination regimens.
Results From a Phase 2 Study Evaluating Ofatumumab for Advanced-Stage Follicular Lymphoma
Ofatumumab was well tolerated by patients with advanced-stage follicular lymphoma but did not appear superior to other monotherapy agents for this disease.
Palbociclib Plus Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
Results from a phase 1 trial suggested that patients with previously treated mantle cell lymphoma may respond positively to ibrutinib plus palbociclib.
FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
The US FDA provided updated information to women with breast implants and their health care providers on the risk of developing a specific type of lymphoma.
A Novel Relapse Risk Stratification Model for Patients With Diffuse Large B-Cell Lymphoma
Researchers combined the International Prognostic Index with cell-of-origin subtype to identify patients at high risk for central nervous system relapse.
Updated WHO-EORTC Classification for Primary Cutaneous Lymphomas
Changes to the WHO-EORTC classification for primary cutaneous lymphomas were highlighted in a recent review article.
Dose-Adjusted Immunochemotherapy May Yield Durable Remission in Aggressive Diffuse Large B-Cell Lymphoma
Patients with MYC-rearranged aggressive diffuse large B-cell lymphoma appeared to achieve durable remission with EPOCH-R.
Researchers Report Early Clinical Promise for Macrophage Checkpoint Blockade
A doublet immunotherapy regimen incorporating the investigational mAb Hu5F9-G4 shows clinical activity in patients with relapsed/refractory non-Hodgkin lymphoma.
CD19 CAR T-Cell Therapies: “Expect an Evolution”
“CD19 CAR therapy has paved the way for a new field of medicine based on the genetic instruction of T-cell responses,” according to Dr Michel Sadelin.
Improved Outcomes for Vitreoretinal Lymphoma With Combined Treatment
Patients who received combined systemic and intraocular treatment had longer failure-free and relapse-free survival.
CAR T Cell Therapy May Yield Durable Response in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Over half of evaluable patients who received an infusion of tisagenlecleucel achieved partial or complete response.
Clinicians Face Uncertainties in Treating Older Patients With Hodgkin Lymphoma
A lack of research focusing primarily on older patients with Hodgkin lymphoma has led to an unmet need for effective, less toxic treatment in this population.
First Rituximab Biosimilar Truxima Gets FDA Approval
The FDA approval was supported by clinical data describing structural and functional characterization, preclinical data, human pharmacokinetic data, clinical immunogenicity data, and other data which showed no clinically meaningful differences between Truxima and Rituxan.
Adcetris Plus Chemotherapy Approved for Peripheral T-Cell Lymphoma
The approval was based on data from a randomized, double-blind, double-dummy, actively controlled trial (ECHELON-2) involving 452 patients with certain PTCLs.
Standard Methodology Needed to Evaluate Pruritus in Cutaneous T Cell Lymphoma
Though the majority of patients with cutaneous T cell lymphomas experience pruritus, the pathophysiology of the symptom is relatively unclear.
Prognostic Value of Minimal Residual Disease in Indolent Lymphomas
Novel molecular technologies for detecting minimal residual disease may offer prognostic value for patients with indolent lymphomas.
Prevention of Hepatitis B Virus Reactivation in Patients With B-Cell Lymphoma
Preemptive nucleos(t)ide analog treatment (NAT) was associated with decreased risk of HBV reactivation in patients receiving immunochemotherapy.
Long-Term Survival in Patients With Advanced Stage Hodgkin Lymphoma
Researchers analyzed long-term follow-up data from 2 clinical trials conducted by the German Hodgkin Study Group.
5-Azacitidine May Lead to Sustained Response in Peripheral T-Cell Lymphoma
Patients with peripheral T-cell lymphomas have a median overall survival of approximately 6 months.
Conflicting Findings of EBV-Biomarker Use in HIV-Related Lymphomas
Conflicting findings regarding the association between plasma Epstein-Barr virus load in PLWHIV and HIV-related lymphomas shows a need for assessment of who benefits from an optimal management of HIV infection and comorbidities.
New Assay May Aid Identification of Primary Mediastinal B-Cell Lymphoma
The current approach to PMBCL diagnosis is not optimal due to the possibility of diagnostic inaccuracy.
Symptomatic Osteonecrosis as a Treatment Complication in Hodgkin Lymphoma
Though osteonecrosis has been previously studied in childhood ALL, it has not been evaluated as a side effect of treatment for Hodgkin lymphoma.
Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
Sequential dosing of brentuximab vedotin before and after standard doxorubicin, vinblastine, and dacarbazine showed a survival benefit in a phase II trial.
Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia
The safety and efficacy of investigational agent zanubrutinib is being evaluated in a head-to-head phase 3 trial in Waldenström macroglobulinemia.
Two Independent Variables Found to Be Prognostic in Diffuse Large B-Cell Lymphoma
Baseline ctDNA levels and, separately, measures of molecular response, were prognostic for outcome in patients with diffuse large B-cell lymphoma.
Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
A retrospective study evaluated the efficacy vs pulmonary toxicity of brentuximab vedotin for relapsed or refractory Hodgkin lymphoma in pediatric patients.
Rituximab Maintenance Improved Long-Term Survival in Elderly With Follicular Lymphoma
A retrospective analysis of outcomes demonstrated the influence of rituximab maintenance after R-CHOP or R-CVP for follicular lymphoma in elderly patients.
Insurance Status Influences Overall Survival in Follicular Lymphoma
Outcomes data demonstrated the impact of socioeconomic status and insurance coverage on outcomes for patients with follicular lymphoma by age (younger than 65 and 65 and older).
All CAR Signaling Domains in Lymphoma Are Not Created Equal
Signal strength of the receptors used to create CAR-T therapies in lymphoma varied depending on the signaling domain chosen for each investigational construct.
Rituximab-Based Immunotherapy May Be As Effective as Chemotherapy in Follicular Lymphoma
Rituximab plus lenalidomide immunotherapy may be an effective alternative to chemotherapy for patients with follicular lymphoma.
RiBVD Effective in the First-Line Setting for Mantle Cell Lymphoma
Researchers sought to determine if the newly formed regimen RiBVD was effective and tolerable in patients older than 65 with mantle cell lymphoma.
Want to read more?
Please login or register first to view this content.
